Metagenomi Therapeutics, Inc. SEC filings MGX

Metagenomi Therapeutics, Inc. has 154 filings in SEC EDGAR's recent list, going back to Aug 16, 2019. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
S-8 Employee stock plan registration Mar 5, 2026 —
S-3 Shelf registration Mar 17, 2025 —
S-8 Employee stock plan registration Mar 17, 2025 —
424B4 Prospectus Feb 12, 2024 —
S-8 Employee stock plan registration Feb 9, 2024 —
S-1/A Amended registration statement Feb 7, 2024 —
S-1/A Amended registration statement Feb 5, 2024 —
S-1/A Amended registration statement Jan 8, 2024 —
S-1 Registration statement Jan 5, 2024 —

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
MGX (Nasdaq)
Fiscal year ends
December 31
Headquarters
Emeryville, CA
SEC filer status
, Emerging growth company
SEC CIK
1785279
Former names
Metagenomi, Inc. (until Jan 12, 2026); Metagenomi Technologies, LLC (until Jan 18, 2024)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.